Study of golidocitinib, azacitidine, and chidamide for T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs for people with peripheral T-cell lymphoma who cannot have intensive chemotherapy. The goal is to see if this treatment works and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of peripheral T-cell lymphoma.
- You should be well enough to care for yourself (ECOG score 0, 1, or 2).
- Your doctor expects you to live at least 12 weeks.
- You must have at least one tumor that can be measured on scans.
- You should not be able to have strong standard chemotherapy (for example, because you are over 60 or have other health issues).
- You must agree to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two targeted drugs – chidamide (an HDAC inhibitor) and golidocitinib (a JAK inhibitor) – for people with peripheral T-cell lymphoma that has come back or hasn't responded to prior treatments. The goal is to see if this combination can shrink tumors or stop the cancer from growing.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
Hear when a new Peripheral T-Cell Lymphoma, Not Classified trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.